161 related articles for article (PubMed ID: 37865067)
41. Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): An updated review.
Dong J; Yuan L; Hu C; Cheng X; Qin JJ
Pharmacol Ther; 2023 Sep; 249():108488. PubMed ID: 37442207
[TBL] [Abstract][Full Text] [Related]
42. Lipid regulation of the ABCB1 and ABCG2 multidrug transporters.
Hegedüs C; Telbisz Á; Hegedűs T; Sarkadi B; Özvegy-Laczka C
Adv Cancer Res; 2015; 125():97-137. PubMed ID: 25640268
[TBL] [Abstract][Full Text] [Related]
43. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters.
Mi YJ; Liang YJ; Huang HB; Zhao HY; Wu CP; Wang F; Tao LY; Zhang CZ; Dai CL; Tiwari AK; Ma XX; To KK; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2010 Oct; 70(20):7981-91. PubMed ID: 20876799
[TBL] [Abstract][Full Text] [Related]
44. The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.
Zhang L; Li Y; Wang Q; Chen Z; Li X; Wu Z; Hu C; Liao D; Zhang W; Chen ZS
Mol Cancer; 2020 Jan; 19(1):10. PubMed ID: 31952518
[TBL] [Abstract][Full Text] [Related]
45. Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro.
Sorf A; Hofman J; Kučera R; Staud F; Ceckova M
Biochem Pharmacol; 2018 Aug; 154():10-17. PubMed ID: 29673999
[TBL] [Abstract][Full Text] [Related]
46. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
Ranjbar S; Khonkarn R; Moreno A; Baubichon-Cortay H; Miri R; Khoshneviszadeh M; Saso L; Edraki N; Falson P; Firuzi O
Toxicol Appl Pharmacol; 2019 Jan; 362():136-149. PubMed ID: 30391378
[TBL] [Abstract][Full Text] [Related]
47. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
[TBL] [Abstract][Full Text] [Related]
48. The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
Hsiao SH; Lusvarghi S; Huang YH; Ambudkar SV; Hsu SC; Wu CP
Cancer Lett; 2019 Mar; 445():34-44. PubMed ID: 30639533
[TBL] [Abstract][Full Text] [Related]
49. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
Dohse M; Scharenberg C; Shukla S; Robey RW; Volkmann T; Deeken JF; Brendel C; Ambudkar SV; Neubauer A; Bates SE
Drug Metab Dispos; 2010 Aug; 38(8):1371-80. PubMed ID: 20423956
[TBL] [Abstract][Full Text] [Related]
50. Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478.
Shi Z; Tiwari AK; Shukla S; Robey RW; Kim IW; Parmar S; Bates SE; Si QS; Goldblatt CS; Abraham I; Fu LW; Ambudkar SV; Chen ZS
Biochem Pharmacol; 2009 Mar; 77(5):781-93. PubMed ID: 19059384
[TBL] [Abstract][Full Text] [Related]
51. Updated chemical scaffolds of ABCG2 inhibitors and their structure-inhibition relationships for future development.
Moinul M; Amin SA; Jha T; Gayen S
Eur J Med Chem; 2022 Nov; 241():114628. PubMed ID: 35944339
[TBL] [Abstract][Full Text] [Related]
52. Natural medicinal compounds target signal transduction pathways to overcome ABC drug efflux transporter-mediated multidrug resistance in cancer.
Bharathiraja P; Yadav P; Sajid A; Ambudkar SV; Prasad NR
Drug Resist Updat; 2023 Nov; 71():101004. PubMed ID: 37660590
[TBL] [Abstract][Full Text] [Related]
53. Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2.
Wu CP; Hsiao SH; Su CY; Luo SY; Li YQ; Huang YH; Hsieh CH; Huang CW
Biochem Pharmacol; 2014 Dec; 92(4):567-76. PubMed ID: 25450670
[TBL] [Abstract][Full Text] [Related]
54. Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters.
Strouse JJ; Ivnitski-Steele I; Waller A; Young SM; Perez D; Evangelisti AM; Ursu O; Bologa CG; Carter MB; Salas VM; Tegos G; Larson RS; Oprea TI; Edwards BS; Sklar LA
Anal Biochem; 2013 Jun; 437(1):77-87. PubMed ID: 23470221
[TBL] [Abstract][Full Text] [Related]
55. A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy.
Peng H; Dong Z; Qi J; Yang Y; Liu Y; Li Z; Xu J; Zhang JT
PLoS One; 2009 May; 4(5):e5676. PubMed ID: 19479068
[TBL] [Abstract][Full Text] [Related]
56. Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines.
Wu CP; Hsiao SH; Murakami M; Lu MJ; Li YQ; Hsieh CH; Ambudkar SV; Wu YS
Cancer Lett; 2017 Nov; 409():56-65. PubMed ID: 28893612
[TBL] [Abstract][Full Text] [Related]
57. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells.
Patel A; Tiwari AK; Chufan EE; Sodani K; Anreddy N; Singh S; Ambudkar SV; Stephani R; Chen ZS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):189-99. PubMed ID: 23673445
[TBL] [Abstract][Full Text] [Related]
58. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
59. Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.
Wu CP; Hsiao SH; Huang YH; Hung LC; Yu YJ; Chang YT; Hung TH; Wu YS
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31941029
[TBL] [Abstract][Full Text] [Related]
60. Epidermal Growth Factor Receptor Inhibitor Mobocertinib Resensitizes Multidrug-Resistant Cancer Cells by Attenuating the Human ATP-Binding Cassette Subfamily B Member 1 and Subfamily G Member 2.
Li YC; Hsiao SH; Murakami M; Huang YH; Chang YT; Hung TH; Wu YS; Ambudkar SV; Wu CP
ACS Pharmacol Transl Sci; 2024 Jan; 7(1):161-175. PubMed ID: 38230272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
